All-In PodcastE1: US Response to COVID-19 & Impact on Startups, VC & Public Markets with David Friedberg
CHAPTERS
- 0:00 – 2:41
Quarantine check-in, show kickoff, and why this episode matters
Jason opens episode one after a successful test run, with the hosts calling in from quarantine. They introduce David Friedberg, joke about Twitter harassment, and frame the episode’s dual crisis: a fast-moving pandemic alongside collapsing markets.
- •Episode one begins after strong response to the pilot
- •Hosts compare quarantine setups and mental state
- •Friedberg’s Twitter experience and online harassment
- •Stock market rapidly deteriorating as backdrop for the discussion
- •Set up: health, policy, and markets are now inseparable
- 2:41 – 6:41
Overreaction vs underreaction: health response, policy shocks, and the market spiral
Friedberg breaks the situation into health, policy, and markets, arguing the biggest risk is making policy without adequate testing data. He warns shutdowns could drive mass unemployment and highlights systemic fragility if industrial shutdowns spread to essential supply chains.
- •Need for broader population testing to understand contagion and fatality
- •Containment policies carry enormous economic consequences
- •Small business, travel, and energy employment exposure
- •Risk of cascading factory shutdowns and food security fears
- •Markets moving from bad to worse; uncertainty dominates
- 6:41 – 9:33
Asymptomatic spread and the ‘denominator problem’ (why fatality rate may be misestimated)
Chamath and Friedberg discuss emerging evidence that many infections may be asymptomatic or mild, which would dramatically change fatality-rate calculations. They cite Korea, the Diamond Princess, NBA testing anecdotes, and papers suggesting large unreported infection pools.
- •Korea data: large young cohort with mild/no symptoms
- •Diamond Princess suggests very high asymptomatic share
- •Early studies imply many infections were unreported in China
- •Fatality rate depends heavily on the true denominator of infections
- •Policy decisions may be based on incomplete/biased sampling
- 9:33 – 13:15
Antibody testing vs PCR: what’s missing, what’s available, and why FDA rules matter
The conversation turns to what kinds of tests are needed and why antibody testing is crucial for epidemiology and reopening plans. Friedberg explains cheap lateral-flow antibody kits, their limitations, and how regulatory friction blocks broad deployment in the U.S.
- •PCR tests detect active shedding; antibody tests reveal prior infection/immunity
- •China manufacturing low-cost antibody kits at scale
- •Non–FDA approved tests circulating via brokers; research use only
- •Sensitivity/specificity tradeoffs are acceptable for population studies
- •U.S. focus remains on PCR throughput rather than broad serology
- 13:15 – 16:23
Treatments and emergency policy: chloroquine, remdesivir, and triage logic
Chamath presses on why the CDC/FDA aren’t giving clearer treatment guidance when early signals suggest potential benefit. Friedberg argues crisis conditions may justify emergency authorization and doctor/patient discretion despite incomplete blinded trials, while acknowledging side-effect risks.
- •Debate: clinical trial rigor vs crisis-time pragmatism
- •Discussion of chloroquine and antivirals as potential tools
- •Doctors’ ‘do no harm’ constraint vs harm from inaction
- •Proposal: manufacture/distribute treatments and let clinicians choose
- •Treatments could reduce fatality and change policy calculus
- 16:23 – 20:06
How deadly is it? Comparing estimated fatality rates and key U.S. risk factors
Jason pushes for an estimated U.S. fatality range; Friedberg contrasts Wuhan vs rest-of-China estimates and the flu. They discuss why Italy is an outlier and note U.S.-specific confounders like obesity/diabetes (A1C) and ICU capacity.
- •Wuhan estimated around ~1.4% in cited paper; rest of China far lower
- •Flu comparison and wide uncertainty bands
- •Italy’s older population and overwhelmed hospitals skew outcomes
- •U.S. ICU capacity may help, but metabolic health may hurt
- •Policy hinges on both fatality and system overload risk
- 20:06 – 22:27
From blanket lockdowns to targeted strategies: age-based shielding, zones, and civil liberties tradeoffs
Chamath argues the choice isn’t binary: society can combine targeted shielding for high-risk groups with aggressive testing and treatment availability. They explore ‘green zones,’ temporary civil-liberty tradeoffs, and the operational challenge of organizing mass testing like an election.
- •Nuanced containment: protect elderly/high-risk more aggressively
- •Use antibody testing to decide when/where to reopen
- •R₀ explained and how herd immunity changes spread dynamics
- •Operational idea: mobilize voting infrastructure/National Guard
- •PCR limits for population screening; serology more useful for reopening
- 22:27 – 29:30
Recording amid a market seizure: why capital markets dysfunction hits everyone
Chamath breaks in to describe extreme real-time dislocations in liquidity and trading. He explains why even people not invested in stocks are affected because capital markets feed banks, lending, startups, and overall economic functioning.
- •Markets as the liquidity engine for the real economy
- •Seizures resemble 2008-style dysfunction
- •Startups and small businesses depend on downstream capital flow
- •Psychological panic can prolong damage beyond fundamentals
- •Maintaining liquidity becomes a crisis-management priority
- 29:30 – 35:15
Startups in crisis: runway math, retraded rounds, and survival over growth
Chamath asks what startup CEOs should do; Jason and Friedberg give tactical guidance. They emphasize closing any available funding immediately, assuming fundraising freezes, cutting burn deeply, and rethinking customer reality as business models shift overnight.
- •Close deals fast; expect term sheets to be pulled or retraded
- •Assume little/no new money for 3–6+ months
- •Cut founder and staff costs to extend runway (examples given)
- •Reevaluate customer willingness/ability to pay in a recession
- •Friedberg’s ‘SIRT gene’ metaphor: shift from growth to healing/survival
- 35:15 – 41:26
VC and LP dynamics: portfolio rebalancing, markdown pressure, and why 36 months runway may be necessary
Chamath explains how LP allocation models break when public markets fall, forcing rebalancing and reduced venture appetite. He predicts delayed but significant markdowns, weaker IRRs, less follow-on support, and a harsher funding environment—so companies should plan for much longer runways.
- •LP portfolios become distorted as liquid assets drop in value
- •LPs may force private valuations to be marked down
- •GPs’ ability to ‘defend’ companies declines as returns deteriorate
- •Activity slows; capital calls and new commitments become harder
- •Recommendation escalates from ~18 months runway to ~36 months
- 41:26 – 44:42
Inside the repo market: leverage, margin calls, and why a ‘roaring back’ rebound is unlikely
Jason asks about a fast containment and market rebound; Chamath argues that’s not the real problem. He gives a plain-English walkthrough of the overnight repo market and how seized funding, leverage unwind, and whipsaw margin calls can create violent capitulation.
- •Fed’s role as liquidity backstop in repo and short-term funding
- •Levered participants rely on continuous refinancing to function
- •When repo seizes, forced selling and de-risking cascade
- •Market dysfunction feeds back into VC, banks, and Main Street credit
- •Bounding the disease with data is prerequisite to financial stabilization
- 44:42 – 54:00
How close are we to mass testing? Near-term PCR ramp vs delayed population serology
They assess timing: PCR availability is improving but doesn’t solve the denominator problem. Friedberg predicts general-population antibody testing isn’t being parallel-pathed, estimating meaningful rollout may still be weeks away, and explains lab bottlenecks and point-of-care limitations.
- •PCR testing improving (multi-day turnaround persists)
- •General population antibody testing still not operationally planned
- •Lab workflows and throughput constraints slow scaling
- •Point-of-care tests exist abroad but face U.S. regulatory barriers
- •Rough estimate: weeks to months for broad serology distribution
- 54:00 – 59:02
Bailouts and buybacks: equity wipeouts, conditions on aid, and ‘compassionate capitalism’
Chamath criticizes corporate financial engineering—especially buybacks funded by free cash flow—followed by demands for bailouts. They debate wiping out equity, protecting taxpayers, curbing executive incentives, and using nationalization/recapitalization to rebuild public balance sheets.
- •Airlines’ buybacks cited as weakening resilience
- •Bailouts should restrict buybacks and executive compensation
- •Debate on who bears equity wipeout: pensions vs institutions
- •Argument for nationalization and later returning proceeds to Treasury
- •Framing: shift toward ‘compassionate capitalism’ and accountability
- 59:02 – 1:12:00
Stimulus scale, GDP hole, and a consumer reset: from luxury spending to resilience
Chamath argues for far larger direct payments than typical proposals, noting U.S. dollar primacy and global weakness. Friedberg translates shutdown time into GDP loss, while the group discusses behavioral shifts away from conspicuous consumption and toward essentials and social cohesion.
- •Proposal: large recurring cash payments to citizens to bridge shutdown
- •GDP math: each month of broad shutdown destroys massive output
- •Leverage makes losses non-linear; plugging holes is complex
- •Expect reduced discretionary/luxury demand; values recalibrate
- •Broader thesis: resilience over just-in-time efficiency
- 1:12:00 – 1:16:59
Healthcare system lessons and regulatory reform: speed, ‘right to try,’ and preparedness
Jason asks what COVID reveals about U.S. healthcare failures. Friedberg argues there’s no simple nationalized-vs-private fix, but regulatory burden slowed diagnostics and treatments; crisis policy should shift toward enabling faster experimentation and deployment while preserving innovation incentives.
- •NHS/other national systems also have serious constraints
- •China’s speed partly came from bypassing approvals and red tape
- •U.S. ‘do no harm’ can cause harm via delayed action
- •Potential expansion of right-to-try and diagnostic flexibility
- •Avoid government-directed R&D; keep incentives while reducing friction
- 1:16:59 – 1:24:12
Wet markets, geopolitics, and the future of globalization: monoculture vs common standards
They address the politically charged debate over naming the virus and U.S.–China tensions, then focus on wet markets as a disease-risk vector. Friedberg calls for shutting them down but notes viruses are ubiquitous; Chamath zooms out to ask what minimum hygiene standards globalization should require and predicts a shift toward national resilience.
- •Wet markets as repeated zoonotic risk; economic/cultural tradeoffs
- •Viruses are everywhere; preparedness matters beyond any single source
- •Question: global trade participation vs shared behavioral standards
- •Risk of monoculture vs preserving cultural and economic diversity
- •Prediction: globalization retreats; supply chains localize for resilience
- 1:24:12 – 1:31:13
When do we eat out and play poker again? Reopening bets and ‘green zone’ optimism
Jason closes by asking for practical timelines: restaurants and normal life. Chamath predicts antibody tests and zoning could enable partial reopening within ~six weeks; Friedberg takes the under, citing West Coast indicators and the economic necessity of reopening—then they end with a personal note about missing their weekly poker game and friends.
- •Reopening framed around antibody tests, IDs, and controlled access
- •Chamath’s optimistic timeline: ~six weeks with ‘green zones’
- •Friedberg’s under bet: early April for West Coast reopening
- •New York expected to lag; ICU/ER data as leading indicators
- •Closing reflections on friendship, priorities, and social infrastructure
